MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.490
-0.020
-0.80%
Closed 16:00 10/28 EDT
OPEN
2.470
PREV CLOSE
2.510
HIGH
2.540
LOW
2.400
VOLUME
132.02K
TURNOVER
--
52 WEEK HIGH
6.05
52 WEEK LOW
2.317
MARKET CAP
58.58M
P/E (TTM)
-4.2820
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Association of Pharmaceutical Scientists (AAPS) 2020 PharmSci 360 conference, held virtually this year from October 26 – November 5, 2020.
PR Newswire · 18h ago
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will join Premas Biotech's Co-Founder and Managing Director Dr. Prabuddha Kundu in a webinar titled "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020 at 9:00 am ET. Investors are invited to register for the webinar at: https://zoom.us/webinar/register/WN_63tKqgu9Rcq8ON2cwcKg_w?timezone_id=America%2FNew_York
PR Newswire · 1d ago
Oramed updates on Phase 3 oral insulin studies: protocols submitted to FDA
Oramed Pharmaceuticals (ORMP) jumps 10% premarket after providing the following update on clinical trials. The company has submitted protocols to the FDA for its upcoming studies to evaluate ORMD-0801.ORMD intends to conduct
Seekingalpha · 10/16 13:12
Oramed Issues Shareholder Update On Pivotal Phase 3 Oral Insulin Studies; Co Has Submitted To FDA The Protocols For Upcoming Pivotal Phase 3 Studies
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP)
Benzinga · 10/16 12:43
ORMP: Advancing Toward Phase 3 Program For ORMD-0801
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, is getting ready to initiate two Phase 3 clinical trials after the FDA has reviewed its Phase 3 protocols
Zacks Small Cap Research · 09/22 12:12
Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present at the EASD Annual Meeting, held virtually this year, September 21-25, 2020.
PR Newswire · 09/21 13:25
Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative
PR Newswire · 09/15 12:25
Oramed to Present at H.C. Wainwright Global Investment Conference
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference
PR Newswire · 09/03 13:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORMP. Analyze the recent business situations of Oramed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORMP stock price target is 9.67 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 1.32M
% Owned: 5.63%
Shares Outstanding: 23.53M
TypeInstitutionsShares
Increased
6
63.12K
New
13
311.89K
Decreased
5
41.83K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Independent Director
Kevin Rakin
Chief Executive Officer/President/Director
Nadav Kidron
Chief Financial Officer/Treasurer/Secretary
Avi Gabay
Chief Financial Officer/Treasurer/Secretary
Avraham Gabay
Chief Operating Officer
Joshua Hexter
Chief Scientific Officer/Director
Miriam Kidron
Independent Director
Aviad Friedman
Independent Director
Xiaoming Gao
Independent Director
Arie Mayer
Independent Director
Leonard Sank
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.